The AgilePulse MAX System is an advanced electroporation solution for fast, efficient transfection of up to 10 ml of cell suspension. Specifically engineered for large-volume applications, our system maximizes cellular uptake with minimal heating and short cycle-time to ensure high cell viability in further cell processing.
The AgilePulse MAX System is simple to use. Cells and polynucleotide are suspended in our proprietary BTXpress Cytoporation Medium T or Cytoporation Medium T4 and transferred via sterile syringe to the large volume electroporation chamber where a programmed sequence of electric pulses is applied. First, a sequence of short, high-intensity pulses opens pores in the cell membranes. These are followed by long, low-intensity pulses that drive the material into cells via electrophoresis. Our patented PulseAgile technology optimizes these pulse parameters to maximize efficiency and cell viability.
The system includes a user-friendly, programmable waveform generator with patented PulseAgile technology, our patent-pending large-volume electroporation chamber, and proprietary BTXpress Cytoporation Medium T, optimized for large volume electroporation. The system is engineered to provide uniform electric fields in a stable temperature environment for excellent cell viability.
- Scale-up—transfection protocols readily scale-up from standard laboratory cuvettes to large-volume transfection in the AgilePulse MAX system.
- Maximal Efficiency with Cytoporation Medium—BTXpress Cytoporation Medium T used with the AgilePulse MAX system has been optimized for maximal efficiency with a number of cell lines, including K562, A20, HEK293 and CHO-KI. It is compatible with a large range of transfectants including DNA, RNA, siRNA, and olignonucleotides. It can be directly diluted in complete growth medium for post-electroporation cell culture.
- Simple User Interface—all controls are operated with the simple touch screen on the front panel. Data is quickly retrieved by USB key and can be analyzed for detailed pulse characteristics including pulse and pulse current.
- Pulse Agile® Advantage—transfection efficiency and cell viability are enhanced by specialized, programmable electrical pulse waveforms, particularly important for larger polynucleotide delivery such as DNA plasmids. The patented Pulse Agile technology combines a unique sequence of short high-intensity pulses to porate cell membranes, followed by long low-intensity pulses to further drive transfectants into cells via electrophoresis, while maintaining cell viability.
No license is required for research use of the AgilePulse MAX System but may be required for clinical and therapeutic use. Please contact BTX Technical Support for more information.
|Item #||Product||Included Items|
|47-0200N||AgilePulse MAX Large Volume Transfection System||AgilePulse MAX Generator, Large Volume Chamber Stand, Safety Stand, 5 ml Chamber,(2X),
Cytoporation Medium T, 500 ml, and 4 mm gap Cuvettes
|47-0201N||AgilePulse MAX Generator Only||AgilePulse MAX Generator only|
No license is required for research use of the AgilePulse MAX System but may be required for clinical and therapeutic use. Please contact BTX for more information.
|User Interface||Touch Screen Display, Footswitch|
|Voltage Range||50 to 1,000 Volts|
|Pulse Width Range||0.050 to 10 ms|
|Pulse Interval||0.200 to 1,000 ms (5 kHz to 1 Hz)|
|Pulse Amplitude||50 to 1,200 Volts|
|Data Export||USB Flash Drive|
|Dimensions (W x H x D)||32 cm x 20 cm x 40 cm
(12.6 x 7.9 x 15.7 in)
|Weight||25 lb (11.3 kg)|
|Operating Temperature||10 to 40oC|
|Mains Voltage||100 to 250 VAC|
|Fuse||240 V, 5 Amp, Slo-Blo, 5 mm x 20 mm|
- CRISPR transfections
- Transfect cells such as bone marrow to produce or replace a missing protein
- Deliver siRNA to suppress gene expression
- Deliver genes for permanent gene correction
- Load cells with a drug for drug delivery
- Cancer immunotherapy
- Transfect eukaryotic cells for protein production in bioreactors
- Large-scale production of replication-deficient viruses
|47-0203||AgilePulse MAX Safety Stand for Cuvettes|
|47-0209||AgilePulse MAX Safety Stand for Flatpack|
|47-0202N||AgilePulse MAX Chamber Holder for Large Volume 5 ml Chambers|
|45-0134||Cuvette Plus, 1 mm gap, 90 µl, Sterile Pkg/10, Gray|
|45-0124||Cuvette Plus, 1 mm gap, 90 µl, Sterile Pkg/50, Gray|
|45-0135||Cuvette Plus, 2 mm gap, 400 µl, Sterile Pkg/10, Blue|
|45-0125||Cuvette Plus, 2 mm gap, 400 µl, Sterile Pkg/50, Blue|
|45-0136||Cuvette Plus, 4 mm gap, 800 µl, Sterile Pkg/10, Yellow|
|45-0126||Cuvette Plus, 4 mm gap, 800 µl, Sterile Pkg/50, Yellow|
|47-0206||Flatpack Chambers, 4 mm gap, 10 ml volume, pkg. of 10|
|47-0204N||AgilePulse Large Volume Chamber, 6 mm gap, 5 ml, 2 ports w/fittings|
|47-0010||AgilePulse Large Volume Chamber, 6 mm gap, 5 ml, 4 ports|
|47-0002||BTXpress Cytoporation Low Conductivity Medium T, 500 ml volume|
Andreason GL, Evans GA. Optimization of electroporation for transfection of mammalian cells. Anal. Biochem. 1989 Aug 1;180:269-275.
Bartoletti,DC, Harrison G I, Weaver JC. The number of molecules taken up by electroporated cells: quantitative determination. FEBS Lett. 1989 Oct 9;256:4-10.
Buck, JA, Hayt WH. Engineering Electro-Magnetics, 9th Edition. New York:McGraw Hill;2012.
Chang, DC, Chassy BM, Saunders JA and Sowers AE, eds. Guide to Electroporation and Electrofusion. San Diego: Academic Press;1992.
Dimitrov DS, and Sowers AE. Membrane electroporation - fast molecular exchange by electroosmosis. Biochimica et Biophysica Acta. 1990 1022:381-392.
Disalvo EA and Simon SA, eds. Permeability and Stability of Lipid Bilayers. Boca Raton: CRC Press;1995.
Djuzenova CS, Zimmermann U, Frank H, Sukhorukov VL, Richter E, Fuhr G. Effect of medium conductivity and composition on the uptake of propidium iodide into electropermeabilized myeloma cells. Biochimica et Biophysica Acta. 1996;1284:143-152.
Feucht J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature Medicine. 2019;25:82-88.
Golzio M, Teissie J, Rols MP. Direct visualization at the single-cell level of electrically mediated gene delivery. Proc Natl Acad Sci USA. 2002 Feb 5;99(3):1292-7.
Jenkins MJ, Farid SS. Cost-effective bioprocess design for the manufacture of allogeneic CAR-T cell therapies using a decisional tool with multi-attribute decision-making analysis. Biochem Engin J. 2018;137:192-204.
Klenchin VA, Sukharev SM, Chernomordik LV, Chizmadzhev YA, Electrically induced DNA uptake by cells is a fast process involving DNA electrophoresis. Biophys J. 1991;60:804-811.
Lee SWL, et al. Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model. Front Immunol. 2018 Mar 6;9:416. doi: 10.3389/fimmu.2018.00416. eCollection 2018.
Markovic SN, et al. Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. J Transl. Med. 2006 Aug 15;4:35-48.
McCreedy BJ, Senyukov VV, Nguyen KT. Off the shelf T cell therapies for hematologic malignancies. Best Practice and Research: Clinical Haematology. 2018 Jun 31;2:166-175.
Moyer LS. A suggested standard method for the investigation of electrophoresis. J Bacteriol. 1936 May; 31(5):531-546.
Neumann E, Kakorin S, Toensing K. Fundamentals of electroporative delivery of drugs and genes. Bioelectrochem Bioenerg. 1999;48:3-16.
Neumann E, Rosenheck K. Permeability changes induced by electric impulses in vesicular membranes. J Membr. Biol. 1972 Dec 29;10:279-290.
Neuman E, Toensing K, Kakorin S, Budde P, Frey J. Mechanism of electroporative dye uptake by mouse B cells. Biophys J. 1998;74:98-108.
Neuman E, Sowers AE, and Jordan C.A, eds. Electroporation and Electrofusion in Cell Biology. New York: Plenum Press;1989.
Nickoloff, Jac A., ed. Plant Cell Electroporation and Electrofusion Protocols. Methods in MolecularBiology, Volume 55. Totowa, New Jersey:Humana Press;1995.
Rathert P, et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015 Set24;525(7570):543-547.
Valton J, et al. A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies. Nature Sci Rep. 2018;8: 8972.